SG11201604759UA - A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation - Google Patents
A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammationInfo
- Publication number
- SG11201604759UA SG11201604759UA SG11201604759UA SG11201604759UA SG11201604759UA SG 11201604759U A SG11201604759U A SG 11201604759UA SG 11201604759U A SG11201604759U A SG 11201604759UA SG 11201604759U A SG11201604759U A SG 11201604759UA SG 11201604759U A SG11201604759U A SG 11201604759UA
- Authority
- SG
- Singapore
- Prior art keywords
- nicotinamide
- pharmaceutical composition
- composition containing
- aminosalicylic acid
- intestinal microbiota
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13197261 | 2013-12-13 | ||
| PCT/EP2014/077637 WO2015086838A2 (fr) | 2013-12-13 | 2014-12-12 | Composition pharmaceutique contenant des combinaisons de nicotinamide et de 5-acide aminosalicylique pour influencer de manière bénéfique la microbiote intestinale et/ou traiter une inflammation gastrointestinale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201604759UA true SG11201604759UA (en) | 2016-07-28 |
Family
ID=49765381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604759UA SG11201604759UA (en) | 2013-12-13 | 2014-12-12 | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10758552B2 (fr) |
| EP (1) | EP3079704B1 (fr) |
| JP (1) | JP6554468B6 (fr) |
| KR (1) | KR20160088436A (fr) |
| CN (1) | CN105813644B (fr) |
| AU (1) | AU2014363430A1 (fr) |
| CA (1) | CA2932504A1 (fr) |
| ES (1) | ES2716115T3 (fr) |
| HK (1) | HK1223840A1 (fr) |
| IL (1) | IL245890A0 (fr) |
| MX (1) | MX2016007323A (fr) |
| PH (1) | PH12016501059A1 (fr) |
| SG (1) | SG11201604759UA (fr) |
| WO (1) | WO2015086838A2 (fr) |
| ZA (1) | ZA201603629B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3079675T3 (pl) | 2013-12-13 | 2020-07-27 | Conaris Research Institute Ag | Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid do zastosowania w korzystnym wpływaniu na poziom lipidów we krwi poprzez modyfikowanie mikrobioty jelitowej |
| AU2014363430A1 (en) | 2013-12-13 | 2016-06-16 | Conaris Research Institute Ag | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
| CN105287561A (zh) * | 2015-11-25 | 2016-02-03 | 上海交通大学医学院附属瑞金医院 | 一种治疗溃疡性结肠炎的药物组合物 |
| US10874617B2 (en) | 2016-04-19 | 2020-12-29 | Ferring B.V. | Oral pharmaceutical compositions of mesalazine |
| ES2848575T3 (es) * | 2016-04-19 | 2021-08-10 | Conaris Res Institute Ag | Composiciones farmacéuticas orales de nicotinamida |
| JP2019534300A (ja) * | 2016-11-09 | 2019-11-28 | エンジーン，インコーポレイティド | プログラム細胞死リガンド１の腸管発現 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| US5736532A (en) * | 1996-02-14 | 1998-04-07 | Furda; Ivan | Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan |
| GB9614902D0 (en) | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| IT1311924B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| GB0015242D0 (en) | 2000-06-22 | 2000-08-16 | Nycomed Amersham Plc | Stabiliser for radiopharmaceuticals |
| AU2001278699A1 (en) | 2000-08-08 | 2002-02-18 | Shionogi And Co., Ltd. | Inflammatory cytokine production inhibitors |
| US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| AU2004314731B2 (en) | 2004-01-20 | 2011-07-07 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods of treatment for inflammatory diseases |
| US20060264409A1 (en) | 2004-01-20 | 2006-11-23 | Harty Richard F | Compositions and methods of treatment for inflammatory diseases |
| EP1753734A1 (fr) * | 2004-05-05 | 2007-02-21 | Renopharm Ltd. | Donneurs d'oxyde nitrique et utilisations de ceux-ci |
| EP1751096A4 (fr) | 2004-05-27 | 2009-01-07 | Antibe Therapeutics Inc | Sel d'acide 4- ou 5- aminosalicylique |
| EP2444071A1 (fr) | 2004-09-27 | 2012-04-25 | Sigmoid Pharma Limited | Formulations comprenant des minicapsules |
| JPWO2007004613A1 (ja) | 2005-07-01 | 2009-01-29 | 味の素株式会社 | 炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤 |
| UA104274C2 (ru) * | 2006-07-18 | 2014-01-27 | Антиб Холдингз Инк. | Сероводородные производные нестероидных противовоспалительных лекарственных средств |
| US7920752B2 (en) * | 2006-08-17 | 2011-04-05 | Brother Kogyo Kabushiki Kaisha | Image processing device that quickly performs retinex process |
| ITMI20061932A1 (it) * | 2006-10-09 | 2008-04-10 | Carlo Ghisalberti | Complessi a trasferimento di carica per uso medicale |
| US20090104171A1 (en) | 2007-10-19 | 2009-04-23 | Pardee Joel D | Metabolic Enhancement Therapy |
| US20110104282A1 (en) | 2008-04-25 | 2011-05-05 | Karolinska Institutet Innovations Ab | New Therapy of Treatment of the Irritable Bowel Syndrome |
| EP2296709A4 (fr) | 2008-06-02 | 2012-02-01 | Reddys Lab Ltd Dr | Formulations de niacine à libération modifiée |
| NZ592049A (en) | 2008-10-03 | 2012-11-30 | Falk Pharma Gmbh | Compositions and methods for the treatment of bowel diseases with granulated mesalamine |
| JP2011121889A (ja) | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用アミノ酸組成物 |
| JP2012102054A (ja) | 2010-11-11 | 2012-05-31 | Kyodo Milk Industry Co Ltd | 腸内ポリアミン増強剤 |
| WO2012090224A1 (fr) | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Nouveaux co-cristaux/ sels moléculaires de mésalamine s'utilisant comme médicament anti-inflammatoire amélioré |
| US10426765B2 (en) | 2012-06-15 | 2019-10-01 | Conaris Research Institute Ag | Pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| WO2014200347A1 (fr) | 2013-06-14 | 2014-12-18 | Ferring B.V. | Formulation de nicotinamide à libération prolongée |
| AU2014363430A1 (en) | 2013-12-13 | 2016-06-16 | Conaris Research Institute Ag | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
| PL3079675T3 (pl) | 2013-12-13 | 2020-07-27 | Conaris Research Institute Ag | Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid do zastosowania w korzystnym wpływaniu na poziom lipidów we krwi poprzez modyfikowanie mikrobioty jelitowej |
| ES2848575T3 (es) | 2016-04-19 | 2021-08-10 | Conaris Res Institute Ag | Composiciones farmacéuticas orales de nicotinamida |
-
2014
- 2014-12-12 AU AU2014363430A patent/AU2014363430A1/en not_active Abandoned
- 2014-12-12 MX MX2016007323A patent/MX2016007323A/es unknown
- 2014-12-12 US US15/103,406 patent/US10758552B2/en active Active
- 2014-12-12 ES ES14818934T patent/ES2716115T3/es active Active
- 2014-12-12 CN CN201480066650.4A patent/CN105813644B/zh active Active
- 2014-12-12 CA CA2932504A patent/CA2932504A1/fr not_active Abandoned
- 2014-12-12 WO PCT/EP2014/077637 patent/WO2015086838A2/fr active Application Filing
- 2014-12-12 KR KR1020167018717A patent/KR20160088436A/ko not_active Application Discontinuation
- 2014-12-12 EP EP14818934.3A patent/EP3079704B1/fr active Active
- 2014-12-12 JP JP2016538792A patent/JP6554468B6/ja active Active
- 2014-12-12 SG SG11201604759UA patent/SG11201604759UA/en unknown
-
2016
- 2016-05-26 IL IL245890A patent/IL245890A0/en unknown
- 2016-05-27 ZA ZA2016/03629A patent/ZA201603629B/en unknown
- 2016-06-02 PH PH12016501059A patent/PH12016501059A1/en unknown
- 2016-10-24 HK HK16112200.3A patent/HK1223840A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3079704A2 (fr) | 2016-10-19 |
| PH12016501059A1 (en) | 2016-07-11 |
| KR20160088436A (ko) | 2016-07-25 |
| MX2016007323A (es) | 2016-09-09 |
| HK1223840A1 (zh) | 2017-08-11 |
| JP2016540011A (ja) | 2016-12-22 |
| AU2014363430A1 (en) | 2016-06-16 |
| ES2716115T3 (es) | 2019-06-10 |
| US10758552B2 (en) | 2020-09-01 |
| IL245890A0 (en) | 2016-07-31 |
| CA2932504A1 (fr) | 2015-06-18 |
| WO2015086838A3 (fr) | 2015-10-08 |
| EP3079704B1 (fr) | 2019-01-02 |
| JP6554468B2 (ja) | 2019-07-31 |
| CN105813644B (zh) | 2020-07-10 |
| US20160317557A1 (en) | 2016-11-03 |
| CN105813644A (zh) | 2016-07-27 |
| ZA201603629B (en) | 2019-04-24 |
| WO2015086838A2 (fr) | 2015-06-18 |
| JP6554468B6 (ja) | 2019-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1248712A1 (zh) | 氘代鵝去氧膽酸衍生物以及包含該化合物的藥物組合物 | |
| IL256085B (en) | A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment | |
| HK1223840A1 (zh) | 用於有益地影響腸道微生物叢和/或治療胃腸道炎症的含有煙醯胺和 -氨基水楊酸的組合的藥物組合物 | |
| HK1204972A1 (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota // | |
| PT3031826T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção do cancro | |
| GB201402071D0 (en) | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PT3079675T (pt) | Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinal | |
| PT3277295T (pt) | Composição para o tratamento de um estado metabólico patogénico da flora intestinal e de doenças derivadas | |
| ZA201604225B (en) | Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus | |
| EP2962693A4 (fr) | Composition pharmaceutique pour la prévention et/ou le traitement d'un cancer | |
| SG10202008700VA (en) | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| GB201406172D0 (en) | Therapy and pharmaceutical composition | |
| IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
| IL245414A0 (en) | A process for the preparation of methylphenidate and its pharmaceutical salts | |
| RS58983B1 (sr) | Čvrsta farmaceutska kompozicija citizina i postupak za njeno dobijanje | |
| GB201718483D0 (en) | Pharmaceutical composition for treatment of meopausal syndrome and preparation method thereof | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| KR101583452B9 (ko) | 위장질환 치료용 의약 조성물 | |
| GB201511863D0 (en) | Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same | |
| GB201317935D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | |
| GB201317932D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | |
| GB201308137D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | |
| EP3156051A4 (fr) | Composition pharmaceutique combinant un anticonvulsivant et un dérivé de l'acide nicotinique |